NEW YORK (360Dx) – Chembio Diagnostics said today that it has entered a collaboration with LumiraDx to develop point-of-care diagnostic tests for infectious diseases to address "significant global health threats."

Chembio said that it will receive funding from LumiraDx subject to satisfying certain milestones. If the tests receive regulatory approval and are commercialized in accordance with the agreement, Chembio will obtain royalty payments on resulting product sales and sell reagents to LumiraDx.

Additional terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
26
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 

Mar
19

In this webinar, Dr. Matthew Faron, a pathologist from the Medical College of Wisconsin, will share results of a comparison study of three rapid influenza assays.

 

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.